Pheast Therapeutics
Home - Pheast
United States · $101.0M raised
- Headquarters
- California
- Employees
- 11–50
- Business Model
- B2B
- Website
- pheast.com
- Total Funding
- $101.0M
- Last Round
- $25.0M Series BApr 2022
- Rounds
- 2
About
Pheast Therapeutics is a clinical-stage immuno-oncology company developing macrophage checkpoint inhibitors to activate the innate immune system against cancer.
Summary
Pheast Therapeutics is a Biotech company based in United States. It has raised $101.0M in total across 2 rounds, most recently a $25.0M Series B round in Apr 2022. Investors include ARCH Venture Partners, Catalio Capital Management and Alexandria Venture Investments.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...